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Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz)
requires direct comparisons of the new drug with appropriate comparators determined by the Federal Joint Committee
(G-BA). In case no head-to-head studies are available for direct comparisons, the submission of indirect comparisons is
permitted to assess the additional benefit of the new drug. However, the Institute for Quality and Efficiency in Health
Care (IQWiG) states a clear preference for head-to-head trials and defines strict requirements for indirect comparisons to
be considered in the benefit assessment. Similar requirements also exist in other countries with mandatory health
technology assessments (HTA), like France, England and Scotland. Our evaluation shows that a comparison of the
different HTA regarding indirect comparisons is difficult. Overall, external preconditions and methodological requirements
are demanding and hardly to fulfill by pharmaceutical companies for implementation of indirect comparisons in early
benefit assessment. The determination of the appropriate comparators, outcomes, patient subgroups and study choice
are the main target within indirect comparisons for the future. To compare and assess submitted indirect comparisons
it would be desirable that a transparent process was established, including the mandatory publication of HTA-reports
within Europe and international guidelines, accepted by a large number of HTA-agencies.
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Since the AMNOG came into force in 2011, all pharma-
ceutical companies have to present clinical evidence to
proof an additional benefit of new substances compared
to appropriate comparators. The early benefit assessment
in Germany under AMNOG requires direct comparisons
with one of the appropriate comparators determined by
the G-BA for each therapeutic indication to provide
clinical evidence of their product. Since 2013 the G-BA
allows more than one appropriate comparator and it is up
to the pharmaceutical company to choose one of these. In
case no head-to-head studies are available, the submission
of indirect comparisons is permitted to assess the
additional benefit of the new drug. However, the IQWiG* Correspondence: splantoer@de.imshealth.com
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in any medium, provided the original work is pstates a clear preference for head-to-head trials and de-
fines strict requirements for indirect comparisons to be
considered in the benefit assessment. Similar require-
ments are also existent in other countries with mandatory
HTA, like England, France and Scotland. Besides, a joint
development of methodological approaches between
different European countries began. This is necessary as
statisticians and scientists face the same HTA-problems.
Definition and methodology of indirect comparisons
The gold-standard to compare efficacy, effectiveness and
safety of interventions in healthcare are randomized,
active controlled trials. The need of an indirect compari-
son arises when no head-to-head trials are available to
perform a direct comparison of two different interven-
tions. Indirect comparisons can be performed as adjusted
indirect comparisons, unadjusted indirect comparisons
and mixed-treatment-comparisons (MTC). Despite of thean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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in adjusted indirect comparisons [1-4].
Adjusted indirect comparison
Bucher’s method is the most common and accepted ap-
proach for an adjusted indirect comparison of two interven-
tions A vs. B [4]. Adjusted indirect comparisons preserve the
strength of randomization by comparing the (pooled) rela-
tive effect estimate of intervention A vs. X with the (pooled)
relative effect estimate of intervention B vs. X (X as common
comparator), as in Figure 1 with common comparator X.
Placebo is often used as a common comparator [2-5].
Unadjusted indirect comparison
An unadjusted indirect comparison is defined as the
naïve use of single study arms to combine study data as
if coming from a single large trial. A summary effect is
computed for all study arms involving intervention A
and compared to a summary effect for all study arms in-
cluding intervention B. These two summary measures
(cohorts) of the effect of intervention A and intervention
B will be compared to establish the relative effectiveness
of intervention A to intervention B. Data of comparative
arms will not be used, as shown in Figure 1. Thereby the
randomized nature of individual trials is compromised.
It is recommended to avoid unadjusted indirect compari-








Studies with Intervention B
Study 1 B vs. X
Study 2 B vs. X
Study 3 B vs. X
Study 4 B vs. F
Study 5 B vs. F
Study 6 B vs. G
Study 7 B vs. H
Θ B vs. X
Studies with Intervention A
Study 1 A vs. X
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Study 3 A vs. X
Study 4 A vs. X
Study 5 A vs. C
Study 6 A vs. D
Study 7 A vs. E
Θ A vs. X
Θ (A vs. X) Θ (B vs. X)
Adjusted indirect comparison
A, B, C, D, E, F, G, H, X: therapeutic effects of interventions
X: Common comparator for indirect comparison
Figure 1 Adjusted and unadjusted indirect comparisons. Source: [3,5],Mixed-treatment-comparisons (MTC)
In the last years, an increased performance of MTC could
be observed in the publications of indirect comparisons.
MTC are also known as network meta-analyses. They
compare more than two different treatments simultan-
eously. MTC allow the combination of indirect and direct
comparisons, incorporation of multiple common compar-
ators and the use of a larger overall number of trials
[3,5,8,9]. Within a MTC, there are often used networks
with geometrical structures. Possible structures of
networks are shown in Figure 2.
Bayesian and frequentist approach
Bayesian approaches are common methods within MTC
as direct and indirect evidence can be combined. The
Bayesian approach uses point estimates and credibility
intervals to give easy and uncontroversial results in
probability theory as traditional statistical methods and
is therefore more flexible. In general, Bayesian methods
use the Bayes-Theorem to interpret the unknown
estimate by converting outcomes of one or more trials
of a prior probability distribution in a posterior distribu-
tion – likelihood estimation. External evidence (also from
non-RCTs) and the form in which conclusions are drawn
are the contributors for decision making [5,6,10-12].
Commonly, the frequentist approach is used in direct
comparisons [6,12], but as researches show, the use intudies with Intervention A
tudy 1 A vs. X
tudy 2 A vs. X
tudy 3 A vs. X
tudy 4 A vs. X
tudy 5 A vs. C
tudy 6 A vs. D
tudy 7 A vs. E
∑ A
Studies with Intervention B
Study 1 B vs. X
Study 2 B vs. X
Study 3 B vs. X
Study 4 B vs. F
Study 5 B vs. F
Study 6 B vs. G
Study 7 B vs. H
∑ B
∑ A ∑ B
Unadjusted indirect comparison
Θ: Estimate of pooled effect (e.g. log odds ratio, means)


















Figure 2 Networks in MTC and their geometrical structure.
Source: [5], adapted. Letter A to F are representing trials, X is common
comparator.
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of interest is a fixed state of nature as in contrary to a
Bayesian approach [10]. The frequentist approach is
divided into fixed and random effect methods. A fixed
effect model aggregates outcomes of different trials with
the assumption, that all estimated effects are similar and
differences are coincidences. Uncertainties of the out-
comes can be affected only by the individual trial [5,6,12].
A random effects model calculates with pooled outcomes
with regard to effect differences in different trials. The
variation of effects within trials and between trials is
included in the model [5,12].
Individual participant/patient data (IPD)
The use of IPD is possible within direct and indirect com-
parisons as well as within MTC, which is very common,
in case IPD is available. IPD-Analyses are used to answer
specific questions, e.g. on subgroups, to adjust for con-
founding factors and to increase the power of detectingtreatment effects and sources of heterogeneity [9,13,14].
In the case of IPD in meta-analysis, data from individual
studies is modeled simultaneously within an appropriate
specification of the meta-analysis as for example a random
effects model [13].
If there is no evidence available from direct studies,
unadjusted indirect comparisons can be performed after
applying propensity score matching at the patients in
the treatment arms coming from different studies in
order to overcome the problem of neglecting the
randomization of the individual studies. As a general
limitation of this approach the treatment arms of the
matched population may be only comparable with re-
spect to the known confounders used for matching. An
additional limitation is that a suitable matching partner
is not in general available for every patient– by exclusion
of these patients a new thread of bias can arise.Underlying assumptions of indirect comparisons
The three basic assumptions to use adjusted indirect
and mixed treatment comparisons appropriately are
[1,2,7,15]:
– Homogeneity of results (assumption of common
meta analyses),
– Similarity (comparability of the studies with regard
to effect modifiers) and
– Consistency (comparability of the estimated effect
from direct and indirect evidence).
The analysis of the assumption on similarity can be
carried out by subjective evaluation of the study charac-
teristics and can be supplemented by sub-group analyses
or meta-regression, if necessary. However, statistical
methods to evaluate the assumption on consistency are
currently being developed. There are still many open
methodological questions in this area [16]. The under-
lying assumptions of indirect mixed treatment compari-
sons are shown in Figure 3.IQWiG and G-BA requirements in Germany [7]
In Germany, the IQWiG generally recommends adjusted
indirect comparisons (particularly the approach by Bucher
[4]) and usually rejects unadjusted indirect comparisons
as an invalid analytical method. Due to current unsolved
methodological problems IQWiG also recommends not
using MTC within benefit assessments. The underlying
methodology of an indirect comparison which is used in a
benefit dossier has to be consistent (regarding compara-
bility of effects) and must be described very accurately to
allow a reproduction of the procedure by IQWiG and
G-BA [7,15].
Two sets of trials used in adjusted indirect comparison Direct comparison
(head-to-head)
Pooling of trials comparing 
intervention A with C
Pooling of trials comparing 
intervention B with C
Pooling of trials comparing 
intervention A with B
Adjusted indirect comparison of trial comparing intervention 
A with B, using intervention C as common comparator






and homogeneity of trials
Figure 3 Assumptions underlying adjusted indirect and mixed treatment comparison. Assumptions of the figure are based on a single
common comparator. Source: [16], adapted.
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European countries
France [17]
The Haute Autorité de Santé (HAS) accepts adjusted
indirect comparisons as a valid method of indirect
comparisons. As an inappropriate approach, the naïve
comparison of active arms and the naïve comparison of
point estimates are named. If a direct comparison is pos-
sible, HAS states that even then an indirect comparison
could be useful. A mixed approach (MTC) of direct and
indirect comparisons can be used to assess the validity
of the results of an adjusted indirect comparison. HAS
suggests the use of the following estimates for networks:
Bayesian network meta-analysis (model of Lu/Ades and
Caldwell) and Lumley’s network meta-analysis (mixed
linear model) [17].England [18]
National Institute for Health and Care Excellence (NICE)
recommends to present data from a MTC (includes
adjusted indirect comparisons) if no direct evidence
(head-to-head trials) is available. The MTC should incorp-
orate RCTs comparing at least two of the relevant (inter-
vention or comparator) treatments. It is required to
present a detailed and complete description of the MTC.
In adjusted indirect comparisons and MTC the principals
of good practice for standard pairwise meta-analyses have
to be followed [18].Scotland
It is to assume that Scottish Medicines Consortium
(SMC) leans the acceptance of indirect comparisons
within health technology assessments on the requirements
of NICE. A checklist for manufacturers is provided by
SMC to assess the indirect comparison which was made
in the HTA.A comparison of the acceptance of the different
methods of indirect comparisons of IQWiG, HAS, NICE
and SMC is shown in Table 1.
In addition to the HTA-agencies within Europe, a new
collaboration was created by them to provide guidance
within HTA in Europe: the European Network for
Health Technology Assessment (EUNETHTA).
EUNETHTA Guidance [6]
According to the EUNETHTA Guidance, adjusted indirect
comparisons preserve randomization within trials and
should always be used in preference to unadjusted
methods. Accepted methods are Bucher’s method of
adjusted indirect comparisons, Bayesian and Lumley’s
method of MTC. Recently Bayesian MTC replaced more
and more adjusted indirect comparisons according to
Bucher. Compared to Bucher’s method, Bayesian MTC
can analyze more complex evidence networks and include
more study-level covariates than Bucher [6].
Methods
The aim of this study was to evaluate the relevance of
indirect comparisons in the German early benefit assess-
ment of new drugs and other HTA processes in Europe.
Therefore the submissions of indirect comparisons
assessed by IQWiG within the time frame of January 2011
until February 2014 were comprehensively analyzed.
First, all submissions in Germany were analyzed, to
identify the new drugs within the defined time frame
where submissions contained indirect comparisons.
Second, for each indirect comparison it was determined
which method was applied. Third, the decisions of
IQWiG were analyzed whether the indirect comparison
was accepted or rejected and reasons for rejection were
identified and classified in formal or methodological
deficiencies.
Additionally, a systematic comparison of all German
indirect comparisons with submitted and assessed




IQWiG HAS NICE SMC
Unadjusted •Naïve use of single study arms of different trials (violation of randomization) − − − /
•Application of matching procedures and multivariate analysis
Adjusted •Meta-analytical summary of RCT outcomes + + + /
•Subtraction of realized therapeutic effects (control group vs. verum group(s))
•Comparison of adjusted verum groups
MTC •Combination of evidence from direct and indirect comparisons − + + /
•Basic assumptions of adjusted indirect comparison are applied
•Efficacy ranking of examined therapies
•Bayesian and frequentist approach
+: yes, −: no, /: unknown.
Sources: [7,17,18].
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performed. For this comparison, three European coun-
tries with a comparable and established HTA-process to
Germany and a minimal level of transparency that al-
lows a comparison were chosen: France (HAS), England
(NICE) and Scotland (SMC).
Results
Indirect comparisons submitted to IQWiG
Of all submitted dossiers from manufacturers to IQWiG
until February 2014, 23 indirect comparisons could be
identified. Of these 23 indirect comparisons submitted by
manufacturers the comparison of choice is the adjusted
indirect comparison (n = 14) as required by IQWiG
methods. MTC were submitted in four cases, mostly with
a Bayesian approach. Only five out of 23 were unadjusted
indirect comparisons as shown in Table 2. Reasons for
rejection of indirect comparisons by IQWiG can be classi-
fied in either formal or methodological deficiencies.
Formal deficiencies
Formal deficiencies are defined as a mismatch of the
applied method and the method required by IQWiG and
G-BA. Within formal deficiencies, different reasons for
the rejection of an indirect comparison by IQWiG could
be identified: choice of an appropriate comparator different
to the one determined by the G-BA, formal deficiencies re-
lated to the bibliographic search, formal deficiencies related
to the indirect comparison and incomplete documentation.
One main reason for the rejection of indirect compari-
sons by IQWiG is the choice of an appropriate compara-
tor which differs from the one determined by G-BA.
The choice of an appropriate comparator by the manu-
facturer different to the one determined by G-BA is
legitimate if justified adequately. In all ten cases the
justification of a different choice has been declined and
the indirect comparisons (adjusted indirect comparisons
or MTC) were rejected due to an inappropriate standardtherapeutic approach (Table 2). This was the case for Abir-
aterone acetate, Dapagliflozin, Linagliptin, Perampanel,
Retigabine, Telaprevier, Dabrafenib, Fampridin, Lixisenatid
and Saxagliptin (label extension).
As formal deficiencies related to the bibliographic
search, the incompleteness of the used study pool and an
unclear definition of inclusion criteria for bibliographic
search and data used for each population (Abirateron
acetat) as well as inconsistencies in the search within
study registries (Fingolimod) were criticized.
As formal deficiencies related to the indirect comparison,
missing sensitivity analysis and a non authorized applica-
tion of the comparator within included trials were criti-
cized in the indirect comparison of Sitagliptin.
As incomplete documentation, the required program
code of the indirect comparison (simulated treatment
comparison) was missing in the case of Axitinib (When
an indirect comparison is submitted within the German
benefit assessment, it is required for the manufacturer to
provide the program code in an attachment (Module 5)).
Methodological deficiencies
Methodological deficiencies are defined as an inappropriate
methodology of the indirect comparison, as for example
heterogeneity of study results within MTC, non-similarity of
studies, inconsistencies of outcomes of comparisons. Five
indirect comparisons of Aflibercept, Axitinib, Collagenase
clostridium histolyticum, Ingenolmebutat and Fampridin
were rejected by IQWiG due to the use of an unadjusted
indirect comparison (Table 2), which did not fulfill the
requirements of an adjusted indirect comparison.
In addition, the common comparator was missing or
differing in the indirect comparisons of Ingenolmebutat,
Fampridin, Lixisenatid, Saxagliptin and Vildagliptin. An
inadequate or heterogenic patient population and/or differ-
ing study periods which were included in the comparison
were criticized for Elvitegravier, Cobicistat, Emtricitabin,
Tenofovirdisoproxil, Fampridin, Lixisenatid, Saxagliptin,
Table 2 Evaluation of method used within indirect comparisons submitted to IQWiG and reasons for rejection
Drug substance Trade name Method used for
indirect comparison
Reasons for rejection by IQWiG






•Comparator •Incompleteness of the used study pool
•Inclusion criteria of the bibliographic search
and data used for each population remained unclear
•Formal •Different appropriate comparator as determined
by G-BA
Aclidinium bromide Eklira MTC Bayesian
approach
•Formal •Data was not presented adequately (outcomes
differ from original source, lacking traceability of data,












•Methodology •Comparison does not fulfill the requirements of an
adjusted indirect comparison
•Formal •Description of the simulated comparison (documented
in a







- •Formal •Comparison does not fulfill the requirements of an
adjusted indirect comparison
•Missing common comparator









•Comparator •Methodological mismatch: study population within the
studies used for comparison was not the same as the
indication population
•Methodology •Different appropriate comparator as determined
by G-BA
Fingolimod Gilenya MTC Bayesian
approach






- •Methodology •Comparison does not fulfill the requirements of an
adjusted indirect comparison















•Different appropriate comparator as determined by G-BA
•Examination of a part of the population was criticized
Retigabine Trobalt MTC Frequentist
approach









- •Missing validity of endpoints, quality of trials and evidence
•Methodological restrictions for simple adjusted indirect
comparison
Telaprevir Incivo MTC Bayesian
approach
•Comparator •Different appropriate comparator as determined by G-BA

















•Methodology •Patient population and applied transferability of patient data
cannot be followed
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- •Comparator •Comparison does not fulfill the requirements of an adjusted
indirect comparison
•Patients, who did not receive best supportive care (physiotherapy)
are not similar to patients with placebo treatment (Placebo as
common comparator)







•Comparator •Different appropriate comparator as determined by G-BA in
one indication
•Methodology •Differences in patient population, common comparator and
application of comparators is






•Methodology •Use of inadequate patient population and
study period

















•Methodology •Use of inadequate patient population and study period










•Methodology •Use of inadequate patient population and study period
•Application of comparators is not as authorized within
included trials







•Methodology •Incomplete study pool
•Formal •Heterogeneity of included studies and non consideration of








•Methodology •Use of inadequate patient population and study period
•No statement towards authorization conform patient population
•Differences in used common comparators
aIndirect comparison not in all submitted indications.
Sources: [19-78].
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match in the included indications was another critique
from IQWiG for Dapagliflozin. The heterogeneity of
included studies and the missing consideration of hetero-
geneity within the indirect comparison were also criticized
by IQWiG (Teriflunomid).
In summary the most common rejection reason by
IQWiG of an indirect comparison is a differing appropriate
comparator as determined by G-BA as well as a patient
population (pivotal trial-population) which differs from
population defined in the indication according to the
summary of product characteristics. Rejections due to true
formal deficiencies are rare, as none adequately presented
data or description of the comparison as shown in Table 2.
Comparison to HTA processes in England, France
and Scotland
For the same new drugs, manufacturers submitted six
indirect comparisons to HAS, five to NICE and 12 toSMC. As shown in Tables 1 and 3, there are differences
in the submitted comparisons as well as HTA-dossiers and
available transparency (submitted dossiers, assessment by
HTA-agency etc.) between each country. Additionally, a
dossier including an indirect comparison was not always
submitted to the respective HTA-agency. A comparison
between France and Germany is difficult, due to discrepan-
cies between submitted dossiers regarding drug substance
and applied indirect comparisons, which mostly differ in
each country. In England additional assessments are
performed for new products, besides HTA. Therefore a
comparison of dossiers with indirect comparisons is
challenging as with block scoping reports, policy state-
ments and guidelines the submission of a dossier is not
mandatory for manufacturers. For Scotland, most decisions
by SMC are not transparent regarding the acceptance of
the indirect comparison submitted by the manufacturer.
When comparing the submitted dossiers that involved
an indirect comparison in Germany (IQWiG) with those
Table 3 Evaluation of indirect comparisons submitted to IQWiG, HAS, NICE and SMC
Drug substance Trade name Acceptance of indirect comparison
Germany France England Scotland
Abirateron acetat Zytiga No Yes - -
Aclidinium bromide Eklira No
Aflibercept Eylea - Noe Yes
Axitinib Inlyta No Ongoing Unclear
Collagenase clostridium histolyticum Xiapex - -
Dapagliflozina Forxiga No
Fingolimod Gilenya
Ingenolmebutat Picato - -
Linagliptin Trajenta Unclear
Perampanel Fycompa
Retigabine Trobalt Yes Yes
Ticagrelorb Brilique Yes No - -
Telaprevir Incivo No -
Dabrafenib Tafinlar Ongoing




Saxagliptin (new indication) Onglyza - -
Saxagliptin/Metformin (new indication) Komboglyze
Sitagliptin Januvia, Xelevia Ongoing -c Unclear
Teriflunomid Aubagio - No -
Vildagliptina Galvus, Jalra, Xiliarx -c Uncleard
aIndirect comparison not in all submitted indications.
bIndirect comparison only for STEMI PIC population.
cNo HTA report available due to existence of block scoping report, policy statement, guideline, recommendation and evidence summary.
dIndirect comparison was used as sensitivity analysis to support the primary analysis.
eIndirect comparison of included trials should be taken with caution, due to a high heterogeneity of these trials.
The detailed reasons of rejection of the comparisons in Germany are presented in Table 2.
Sources: [17,19-121].
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(SMC), differences in the assessments of Abirateron acetat
(Zytiga®), Aflibercept (Eylea®), Retigabine (Trobalt®), Tica-
grelor (Brilique®) and Saxagliptin (Onglyza®) were revealed:
Abirateron acetat (Zytiga®) [55,115]
IQWiG decided opposite of HAS against the submitted
indirect comparison of Abirateron acetat. In Germany,
the manufacturer submitted an indirect comparison with
a paired comparison according to Bucher’s method and
Prednison as common comparator. In France, there are
no information or specifications available regarding meth-
odology or common comparator used. In both dossiers
Abirateron acetat was compared with Cabazitaxel. How-
ever, IQWiG did not accept this comparison due to the
fact that Cabazitaxel was not the appropriate comparator
which had been chosen by the G-BA.Aflibercept (Eylea®) [66,98]
In Scotland the indirect comparison of Aflibercept was
accepted by SMC with limitations. The limitations were
applied due to a small number of included trials, hetero-
geneity between trials and patient baseline characteris-
tics. Three types of indirect analyses were submitted by
manufacturer in Scotland: a Bucher analysis, a Bayesian
network analysis (both random effects) and a frequentist
network analysis (fixed effects). In change, an unadjusted
indirect comparison (which was described as a descrip-
tive indirect comparison by the pharmaceutical com-
pany) has been submitted in Germany. Also a common
comparator was missing in the German submission as
well as an appropriate comparator which was not used
as licensed (within trials). Due to this, the submitted
German indirect comparison was not accepted by
IQWiG.
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In the dossier submitted for NICE, a MTC with a Bayesian
approach was conducted and Placebo was used as com-
mon comparator. The comparison was made between
Retigabine and different anticonvulsants, e.g. Lacosamide,
Pregabalin, Zonisamide. The manufacturer submitted an
indirect comparison with Placebo as common comparator
and a comparison with Eslicarbazepin and Lacosamid to
the SMC. In the contrary, an indirect comparison with
dose specific (pair wise comparison with fixed and ran-
dom effects) and dose unspecific (pooled estimates) meta-
analyses was submitted in Germany and failed the IQWiG
assessment. As well as in England and Scotland, Placebo
was the common comparator. The comparison was made
between Retigabine and Lacosamid, which did not corres-
pond to the appropriate comparator (Lamotrigine and
Topiramat) chosen by G-BA.
Saxagliptin (Onglyza®) [72,103]
In the SMC-submission, the manufacturer presented
two adjusted indirect comparisons, using the simple
Bucher method and included three studies with Placebo
as common comparator. In comparison the German
submission included four indirect comparisons for four
indications with different common comparators. An
adjusted indirect comparison (frequentist approach) was
conducted in all four indications and declined by
IQWiG as the chosen comparators did not correspond
to the appropriate comparators chosen by the G-BA.
Ticagrelor (Brilique®) [61,110]
In contrast to the positive assessment of the indirect
comparison for the STEMI-population of Ticagrelor by
IQWiG, HAS did not accept the indirect comparison
which was submitted within the dossier. As far as repro-
ducible both dossiers (German and French) included the
same trials (PLATO and TRITON) as well as the same
common comparator (Clopidogrel). In Germany a simple
adjusted indirect comparison with a frequentist approach
was conducted. In France the specific method was not
described.
In summary, all five indirect comparisons are not com-
parable between Germany and France due to different




In the first year of the benefit assessments there were more
formal deficiencies compared with the last 12 months of
this analysis. As an improvement could be noted that data
is usually presented adequately (e.g. Aclidinium bromide)
and program codes normally are presented (e.g. Axitinib) by
manufacturers. However, the most frequent methodologicaldeficiency is still the application of a comparator differing
from the appropriate comparator defined by G-BA.
In this case benefit assessments were fully declined and
not further evaluated even if the indirect comparison was
adequate and methodologically correct according to
IQWiG (e.g. Linagliptin, Retigabin).
One of the biggest challenges for manufacturers within
the German AMNOG assessment is the MTC – as validity
is depending on the method used. This means the assump-
tions on similarity (comparability of the studies with regard
to effect modifiers) and, in case of a combination of direct
and indirect evidence, the assumptions on consistency
(comparability of the estimated effect from direct and in-
direct evidence) have to be fulfilled. The use of the relevant
population, interventions and inclusion of relevant out-
comes as well as a high level of evidence (RCT) are some
of the requirements for a successfully accepted MTC.
But conflicts occur within patient populations (trial
population vs. indication and authorized subpopulation;
e.g. Perampanel), duration of trials (long vs. short; e.g.
Teriflunomid) and treatment regimens (authorization
vs. trial usage; e.g. Saxagliptin/Metformin). Also, even
with the use of only randomized trials within MTC validity
is at risk due to biases.
As the analysis shows, the rejection of indirect com-
parisons within HTA assessments is very frequent in
Germany. However, a comparison with other European
HTA-agencies does not allow a comparative analysis,
and only reflects a discrepancy within transparency of
data and availability of reports.
Transparency within Europe
To allow a comparison of the different requirements and
acceptance of indirect comparisons across Europe, more
transparency is necessary. It is difficult to perform an
objective comparison due to the discrepancy of available
and feasible public data. Only in Germany, the manufac-
turer’s dossier, HTA assessment, resolution and justifying
reasons are fully available for the public. In addition the
HTA assessment is very detailed and allows a recapitulation
by third parties, which is not always possible in other coun-
tries. Due to that a comparison of HTA-decisions across
Europe for new pharmaceutical products is not feasible.
Methodology within Europe
Within Europe the methodological requirements for an
indirect comparison are similar, as the gold standard is
an adjusted indirect comparison in Germany, France,
England and Scotland (Table 3). However, IQWiG is more
hesitant in accepting new methods as MTC compared
with HAS, NICE and SMC due to open methodological
questions.
One of the major differences within European HTA
agencies is the rejection of indirect comparisons due to
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BA in Germany, which is not known as current practice
in England and Scotland. This is the main reason why
an evaluation of indirect comparisons across Europe is
not feasible. Also, no coherent policy for the acceptance
of indirect comparisons (i.e. none acceptance of
unadjusted indirect comparisons) within HTA-agencies
across Europe could be identified. Rather, different
pre-requisites and expectations have to be met across
Europe when presenting evidence based on indirect
comparisons.
Limitations of indirect comparisons
In case of limited availability of studies or high hetero-
geneity between the available studies, no MTC or indir-
ect comparisons should be performed. In case no
common comparator is available an unadjusted indirect
comparison remains as an option. Unadjusted indirect
comparisons however lead to a higher variety of out-
comes and uncertainties which limit the interpretation
of the results [5].
The validity of a MTC depends on the method: were
unadjusted or adjusted indirect comparisons conducted?
MTC performed with an unadjusted indirect comparison
lead to a higher bias potential and an over- or underestima-
tion of therapeutic outcomes due to loss of randomization
and structural homogeneity [5].
Within indirect comparisons methodological problems
often occur due to the understanding of underlying as-
sumption, in used methods as well as fixed and random
effects, in the assessment of trial similarity (heterogeneity),
in the comparison and combination of evidence as well as
within publication biases [6,16].
Political implications
The presented analysis of the status quo of the acceptance
of indirect comparisons in Germany suggests a high prob-
ability of political implication at the choice of the appropri-
ate comparator. As the appropriate comparator is most
often the cheapest available product (i.e. generic or refer-
ence price) it has to be assumed that cost containment is
one of the main drivers for the decision. The same conclu-
sion was drawn by another publication of indirect compar-
isons which confirms that the German benefit assessment
is depending on the additional benefit of a new product as
well as on the decision of the G-BA for an appropriate
comparator [122].
Conclusion
The number of 23 indirect comparisons submitted
between January 2011 and February 2014 shows that
evidence for direct comparisons is often not available, so
manufacturers have to perform indirect comparisons to
compare their drugs with the appropriate comparatordefined by G-BA. This shows the high importance of
indirect comparisons within the German early benefit
assessment. However, Ticagrelor is the only accepted
indirect comparison in one subpopulation until now. It
was also the first dossier which was assessed by IQWiG
and received no additional benefit in this subpopulation.
All other indirect comparisons were rejected by IQWiG
due to methodological and formal deficiencies. So, the
relevance of indirect comparison in the German benefit
assessment is very limited as almost all indirect compari-
sons have been rejected so far.
At this point, it also has to be stated that the IQWiG
approach is methodologically accurate and in accordance
with the legal framework. However, a different appropri-
ate comparator than chosen by the G-BA is mostly
declined in the assessment with the consequence of
rejection of the indirect comparison and no additional
benefit. This could lead to the question, if the currently
applied methodology to determine the appropriate com-
parators is useful and feasible. Based on that indirect
comparisons are generally accepted within the German
early benefit assessment, the challenge for the future will
be to bring together: the determination of the appropriate
comparator by G-BA and the selection of the appropriate
comparator, study choice and selection of patient sub-
groups by the manufacturer to give indirect comparisons
a higher relevance in Germany.
Despite of the German-specific implications, a com-
parison of the relevance of indirect comparison in the
German early benefit assessment with HTA processes in
England, France and Scotland is not feasible due to dif-
ferential submitted comparisons and a diverging level of
public transparency. To compare and assess submitted
indirect comparisons it would be desirable to establish a
transparent process and a mandatory publication of
HTA-reports within Europe. This is necessary to be able
to learn of methodological deficiencies and acquire new
methods to address heterogeneity and biases within
indirect comparisons.
First approaches to assimilate methodological require-
ments of indirect comparisons within Europe are in pro-
gress as the European guideline from EUNETHTA and the
recently published report of the ISPOR-AMCP-NPC Good
Practice Task Force show [6,123]. But it is not enough to
develop valid methodological approaches to solve hetero-
geneity issues and reduce biases only. International guide-
lines for Europe accepted by national HTA-agencies would
be desirable.
To avoid the need of indirect comparison, manufacturers
could encourage with the HTA agencies to set up study
designs for Phase III trials that allow direct comparisons.
But this would also imply that the different HTA agencies
demand the same methodology and agree on the use of
the same appropriate comparator. As already mentioned,
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is not yet established.
Overall, external preconditions and methodological re-
quirements are demanding and hardly to fulfill. At present,
manufacturers rely on the use of adequate methods (status
quo), the right appropriate comparator and missing formal
deficiencies to submit an indirect comparison which may
be accepted by IQWiG – a methodological discussion with
the current players in the system (manufacturer, IQWiG,
G-BA and scientific leaders) is pending.
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